BioCentury | Feb 7, 2019
Clinical News

Aminex shows MYCN is a regulator of the polyamine pathway

...from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN...
...a new approach to hitting the otherwise undrugggable MYCN target. Increased levels of MYCN (v-myc myelocytomatosis viral related oncogene neuroblastoma derived; NMYC...
...difluoromethylornithine (DFMO) Business: Cancer Indication: Treat neuroblastoma Chris Lieu Aminex Therapeutics Inc. University of New South Wales v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC) Brain...
BioCentury | Feb 1, 2019
Preclinical News

Aminex shows MYCN is a regulator of the polyamine pathway

...from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN...
...a new approach to hitting the otherwise undrugggable MYCN target. Increased levels of MYCN (v-myc myelocytomatosis viral related oncogene neuroblastoma derived; NMYC...
...programs (see "FDA's Pediatric Target Picks" ). Chris Lieu Aminex Therapeutics Inc. University of New South Wales v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC) Brain...
BioCentury | Jan 29, 2019
Distillery Therapeutics

Cancer

...Neuroendocrine tumors Cell culture and mouse studies suggest a MYCN-targeting pyrrole-imidazole polyamide could help treat MYCN-amplified...
...include testing the compound in patient-derived xenograft (PDX) models of MYCN-amplified neuroblastoma. TARGET/MARKER/PATHWAY: v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC...
...24, 2018 doi:10.1158/0008-5472.CAN-18-1198 CONTACT: Hiroki Nagase, Chiba University, Chiba, Japan email: hnagase@chiba-cc.jp Claire Quang Chiba University v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC) Neuroendocrine...
BioCentury | Nov 29, 2018
Translation in Brief

Beyond BRCA

...genomic rearrangements and amplification of v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc) and v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC...
...Staff Writer German Cancer Research Center (DKFZ) Poly(ADP-ribose) polymerase (PARP) v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC...
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

...Myeloid-lymphoid or mixed-lineage leukemia protein; MLL5 - Myeloid-lymphoid or mixed-lineage leukemia 5; MYCN (NMYC) - v-myc myelocytomatosis viral related oncogene neuroblastoma derived...
BioCentury | Apr 10, 2018
Distillery Therapeutics

Cancer

...levels of miR-204 correlated with high tumor levels of MYCN and poor survival. In three MYCN-amplified...
...Next steps could include testing miR-204 mimics in animal models of neuroblastoma. TARGET/MARKER/PATHWAY: v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC...
...Glenn M. Marshall, same affiliation as above email: g.marshall@unsw.edu.au Sandi Wong Lowy Cancer Research Centre MicroRNA-204 (miR-204) v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC) Neuroendocrine...
BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

...and mouse studies suggest inhibiting XBP1 or its activator IRE1 could help treat MYC- or MYCN-driven...
...nucleus signaling 1 (IRE1; ERN1; IRE1A); v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC...
...reticulum to nucleus signaling 1 (IRE1) (ERN1) (IRE1A) v-myc myelocytomatosis viral oncogene homolog (MYC) (c-Myc) v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC) X-box...
BioCentury | Feb 6, 2018
Distillery Therapeutics

Cancer

...sample and mouse studies suggest promoting IGFBP3 expression could help treat MYCN-driven neuroblastoma. In five MYCN-driven...
...in models of MYCN-driven neuroblastoma. TARGET/MARKER/PATHWAY: Insulin-like growth factor binding protein 3 (IGFBP3); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC...
...Boston, Mass. email: kimberly_stegmaier@dfci.harvard.edu Hongjiang Li Dana-Farber Cancer Institute Insulin-like growth factor (IGF) binding protein 3 (IGFBP3) v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...TPMT) 4 1 Ubiquitin protein ligase E3 component n-recognin 5 (UBR5) 4 1 v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC...
BioCentury | Oct 17, 2017
Distillery Therapeutics

Cancer

...inhibiting EZH2 could help treat MYCN -driven neuroblastoma. In patients, low tumor expression of a MYCN-induced...
...treat B cell lymphoma and lymphoma. TARGET/MARKER/PATHWAY: Enhancer of zeste homolog 2 (EZH2); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC...
...School of Medicine, Nagoya, Japan email: kkadoma@med.nagoya-u.ac.jp Hongjiang Li tazemetostat Nagoya University Enhancer of zeste homolog 2 (EZH2) v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN) (NMYC) Neuroendocrine...
Items per page:
1 - 10 of 27